News | April 06, 2022
GE Healthcare and Elekta sign global collaboration agreement
GE Healthcare and Elekta aim to meet the major need for radiotherapy solutions across both developed and developing markets
GE Healthcare and Elekta aim to meet the major need for radiotherapy solutions across both developed and developing markets
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
The MoU proposed investments in hospitals, pharmacies and laboratories in the state
The implementation of ScienceMedia's solutions will ultimately help AMCR collapse patient recruitment and enrollment
The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
Subscribe To Our Newsletter & Stay Updated
